Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening

新生儿血斑 DNA 测序可改善和扩大新生儿筛查

基本信息

项目摘要

DESCRIPTION (provided by applicant): Newborn screening (NBS) is an essential public health program in all 50 states. The falling cost of whole genome/ exome sequencing provides an opportunity to ask whether whole genome analysis (WGA) might serve as a method of cost-effective newborn screening for any and every condition. We will address certain critical questions raised by the application of this technology to NBS. We will use Whole Exome Sequencing (WES) as a cost-effective method of WGA in 1620 newborn blood spots that are linked to the clinical data of the newborns. We will then test WES as a NBS Tool for metabolic and immunological disorders. These data will be used to 1) compare the sensitivity and specificity of mutation data with biochemical testing, 2) identify gene variants that predict which children with certain metabolic disorders are at greater risk for metabolic decompensation, 3) identify mutations in genes responsible for those primary immunodeficiencies that are not detected by the current T-Cell receptor excision circle assay used for severe combined immunodeficiency screening, and 4) scan 9 genes for variants that are clinically important for drug metabolism and would be typical "secondary findings" if WES were to be used as a NBS method. We will also develop a participant protection framework for conducting WGA during the neonatal period, determine the views, perspectives, and value preferences of key stakeholders about using WGA for NBS, collaborate with the UC Hastings Consortium on Law, Science and Health Policy, to identify the legal and constitutional issues for using WGA, and for incorporating PGx into NBS programs, and develop and disseminate policy recommendations for expanded NBS programs based on WGA. RELEVANCE: We plan to test the use of one method of whole genome analysis, whole exome sequencing, as the sole method of newborn screening for disorders currently being screened for and others that are missed by current newborn screening but for which newborn screening might be appropriate. This would provide substantial public health benefit for newborns who might otherwise go undiagnosed and untreated while serious, even irreversible, damage occurs. Equally important, we will explore parents' interest in incidental findings and develop appropriate legal frameworks to make sure NBS by WGA can be done ethically.
描述(由申请人提供):新生儿筛查(NBS)是所有50个州的基本公共卫生计划。全基因组/外显子组测序成本的下降提供了一个机会,让我们思考全基因组分析(WGA)是否可以作为一种具有成本效益的新生儿筛查方法。我们将解决这项技术应用于国家统计局所提出的一些关键问题。我们将使用全外显子组测序(WES)作为WGA的一种具有成本效益的方法,用于与新生儿临床数据相关的1620个新生儿血点。然后,我们将测试WES作为代谢和免疫疾病的NBS工具。这些数据将用于1)比较突变数据与生化检测的敏感性和特异性,2)识别预测哪些突变的基因变异。 患有某些代谢紊乱的儿童处于代谢失代偿的更大风险中,3)鉴定导致那些原发性免疫缺陷的基因中的突变,所述突变不能通过用于严重联合免疫缺陷筛查的当前T细胞受体切除环测定检测到,和4)扫描9个基因的变异,这些变异在临床上对药物代谢很重要,并且是典型的“次要发现”如果WES被用作NBS方法。我们还将制定一个参与者保护框架,用于在新生儿期进行WGA,确定关键利益相关者对使用WGA进行NBS的观点、观点和价值偏好,与加州大学黑斯廷斯分校法律、科学和卫生政策联盟合作,确定使用WGA的法律的和宪法问题,并将其纳入 PGx纳入国家统计局计划,并根据WGA制定和传播扩大国家统计局计划的政策建议。 相关性:我们计划测试使用一种全基因组分析方法,全外显子组测序,作为新生儿筛查目前正在筛查的疾病的唯一方法,以及目前新生儿筛查遗漏的其他疾病,但新生儿筛查可能是合适的。这将为新生儿提供巨大的公共卫生利益,否则他们可能在发生严重甚至不可逆转的损害时得不到诊断和治疗。同样重要的是,我们将探讨家长对偶然发现的兴趣,并制定适当的 法律的框架,以确保WGA的NBS可以道德地完成。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT L NUSSBAUM其他文献

ROBERT L NUSSBAUM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT L NUSSBAUM', 18)}}的其他基金

Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening
新生儿血斑 DNA 测序可改善和扩大新生儿筛查
  • 批准号:
    8882899
  • 财政年份:
    2013
  • 资助金额:
    $ 118.75万
  • 项目类别:
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening
新生儿血斑 DNA 测序可改善和扩大新生儿筛查
  • 批准号:
    8891509
  • 财政年份:
    2013
  • 资助金额:
    $ 118.75万
  • 项目类别:
Combined BAC Transgenic and Knock-Out Mouse Model of Lowe Syndrome Nephropathy
Lowe 综合征肾病的 BAC 转基因和敲除小鼠模型相结合
  • 批准号:
    8449266
  • 财政年份:
    2012
  • 资助金额:
    $ 118.75万
  • 项目类别:
Combined BAC Transgenic and Knock-Out Mouse Model of Lowe Syndrome Nephropathy
Lowe 综合征肾病的 BAC 转基因和敲除小鼠模型相结合
  • 批准号:
    8236723
  • 财政年份:
    2012
  • 资助金额:
    $ 118.75万
  • 项目类别:
Combined BAC Transgenic and Knock-Out Mouse Model of Lowe Syndrome Nephropathy
Lowe 综合征肾病的 BAC 转基因和敲除小鼠模型相结合
  • 批准号:
    8627601
  • 财政年份:
    2012
  • 资助金额:
    $ 118.75万
  • 项目类别:
GI Endotoxin as an Environmental Trigger in an alpha-Synuclein Transgenic Mouse
胃肠道内毒素作为 α-突触核蛋白转基因小鼠的环境触发因素
  • 批准号:
    8305727
  • 财政年份:
    2010
  • 资助金额:
    $ 118.75万
  • 项目类别:
Combined BAC Transgenic and Knock-Out Mouse Model of Lowe Syndrome Nephropathy
Lowe 综合征肾病的 BAC 转基因和敲除小鼠模型相结合
  • 批准号:
    8081385
  • 财政年份:
    2010
  • 资助金额:
    $ 118.75万
  • 项目类别:
GI Endotoxin as an Environmental Trigger in an alpha-Synuclein Transgenic Mouse
胃肠道内毒素作为 α-突触核蛋白转基因小鼠的环境触发因素
  • 批准号:
    8107578
  • 财政年份:
    2010
  • 资助金额:
    $ 118.75万
  • 项目类别:
GI Endotoxin as an Environmental Trigger in an alpha-Synuclein Transgenic Mouse
胃肠道内毒素作为 α-突触核蛋白转基因小鼠的环境触发因素
  • 批准号:
    7985599
  • 财政年份:
    2010
  • 资助金额:
    $ 118.75万
  • 项目类别:
Glucocerebrosidase mutations in a mouse synucleinopathy model
小鼠突触核蛋白病模型中的葡萄糖脑苷脂酶突变
  • 批准号:
    7777864
  • 财政年份:
    2009
  • 资助金额:
    $ 118.75万
  • 项目类别:

相似海外基金

CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
  • 批准号:
    2339759
  • 财政年份:
    2024
  • 资助金额:
    $ 118.75万
  • 项目类别:
    Continuing Grant
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
  • 批准号:
    479334
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
    Operating Grants
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
  • 批准号:
    23H02481
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
  • 批准号:
    2320160
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
    Standard Grant
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
  • 批准号:
    10637251
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
  • 批准号:
    10604822
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
  • 批准号:
    10716621
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
  • 批准号:
    10655891
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
  • 批准号:
    10621634
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
EAGER: Elastic Electronics for Sensing Gut Luminal and Serosal Biochemical Release
EAGER:用于感测肠腔和浆膜生化释放的弹性电子器件
  • 批准号:
    2334134
  • 财政年份:
    2023
  • 资助金额:
    $ 118.75万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了